← All trials
NCT04493151
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2020
- Primary completion
- May 31, 2021
- Completion date
- Aug 31, 2021
- First posted
- Jul 30, 2020
- Last posted
- Jul 30, 2020
- Enrollment
- 8
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hartford HospitalLead sponsor
- MerckCollaborator
- University of ConnecticutSponsor investigator
- University of ConnecticutOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.